Skip to main content

Table 2 Laboratory parameters in all patients and according to ischemic or bleeding complications

From: Ischemic and hemorrhagic abdominal complications in COVID-19 patients: experience from the first Italian wave

 

All patients

N = 30

Ischemic

N = 10

Bleeding

N = 20

p

Leucocytes (109/L)

13.4 (10.6–21.0)

13.9 (10.1–18.3)

13.0 (10.5–22.2)

0.713

 Neutrophils (109/L)

12.2 (8.5–17.4)

12.9 (7.7–15.6)

11.8 (8.8–20.1)

0.846

 Lymphocytes (109/L)

1.4 (0.8–1.6)

1.42 (0.6–3.6)

1.34 (0.8–1.6)

0.880

Platelets (109/L)

242 (172–344)

242 (118–294)

239 (184–356)

0.650

PT-INR

1.18 (1.08–1.58)

1.27 (1.08–1.59)

1.17 (1.08–1.49)

0.456

aPTT

1.23 (1.02–1.73)

1.11 (0.97–2.13)

1.27 (1.12–1.69)

0.604

d-dimer (ng/mL)

3000 (1,367–7740)

8084 (5328–9961)

1771 (1144–3119)

 < 0.001

Fibrinogen (mg/dL)

446 (289–690)

351 (289–836)

657 (259–657)

0.881

CRP (mg/dL)

9.4 (4.5–19.1)

9.4 (3.2–26.2)

9.2 (4.6–14.1)

0.559

IL-6 (pg/mL)a

111 (59–710)

951 (130–7892)

104 (35–193)

0.171

Procalcitonin (μg/mL)

0.43 (0.14–4.31)

2.70 (0.12–20.87)

0.39 (0.15–2.81)

0.397

  1. Data are shown as median (25–75th percentile range). p is the statistical significance by Mann–Whitney test between ischemic and bleeding groups
  2. PT-INR prothrombin time international normalized ratio, aPPT activated partial thromboplastin time, CRP C-reactive protein, IL-6 interleukin-6
  3. aIL-6 measurement was available only for 10 patients (4 in ischemic and 6 in bleeding group)